Michael Chi Sells 7,500 Shares of Hims & Hers Health, Inc. (NYSE:HIMS) Stock

Hims & Hers Health, Inc. (NYSE:HIMS) insider Michael Chi sold 7,500 shares of the company’s stock in a transaction dated Monday, October 21st. The stock was sold at an average price of $22.20, for a total value of $166,500.00. Following the completion of the transaction, the insider now owns 193,980 shares in the company, valued at $4,306,356. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Michael Chi also recently made the following trade(s):

• On Thursday, August 1st, Michael Chi sold 2,054 shares of Hims & Hers Health stock. The stock was sold at an average price of $22.00, for a total value of $45,188.00.

Hims & Hers Health Stock Down 9.4 %

Shares of Hims & Hers Health stock opened at $21.38 on Thursday. The firm has a market cap of $4.59 billion, a PE ratio of 267.22 and a beta of 1.06. The company’s fifty day simple moving average is $17.24 and its two-hundred day simple moving average is $17.73. Hims & Hers Health, Inc. has a 12-month low of $5.65 and a 12-month high of $25.74.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings results on Monday, August 5th. The company reported $0.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.04 by $0.02. Hims & Hers Health had a return on equity of 5.25% and a net margin of 1.70%. The company had revenue of $315.65 million for the quarter, compared to the consensus estimate of $302.43 million. During the same quarter in the previous year, the business earned ($0.03) EPS. Hims & Hers Health’s revenue was up 51.8% compared to the same quarter last year. As a group, sell-side analysts expect that Hims & Hers Health, Inc. will post 0.22 earnings per share for the current fiscal year.

Analysts Set New Price Targets

HIMS has been the subject of a number of research reports. TD Cowen boosted their price target on shares of Hims & Hers Health from $15.00 to $25.00 and gave the stock a “buy” rating in a research note on Thursday, July 11th. Piper Sandler reissued a “neutral” rating and issued a $18.00 target price on shares of Hims & Hers Health in a research note on Tuesday, August 6th. Imperial Capital lowered Hims & Hers Health from an “outperform” rating to an “in-line” rating in a research note on Friday, August 9th. Truist Financial increased their price objective on Hims & Hers Health from $13.00 to $23.00 and gave the company a “hold” rating in a research report on Thursday, July 18th. Finally, Bank of America boosted their target price on Hims & Hers Health from $23.00 to $25.00 and gave the stock a “buy” rating in a research report on Monday. Eight equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat, Hims & Hers Health has an average rating of “Moderate Buy” and an average price target of $20.21.

Hedge Funds Weigh In On Hims & Hers Health

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. raised its holdings in Hims & Hers Health by 1.0% in the 1st quarter. Vanguard Group Inc. now owns 14,310,192 shares of the company’s stock worth $221,379,000 after purchasing an additional 136,907 shares in the last quarter. Renaissance Technologies LLC raised its stake in Hims & Hers Health by 113.1% in the second quarter. Renaissance Technologies LLC now owns 6,039,408 shares of the company’s stock worth $121,936,000 after buying an additional 3,205,108 shares in the last quarter. Farallon Capital Management LLC boosted its position in Hims & Hers Health by 3,890.5% during the 1st quarter. Farallon Capital Management LLC now owns 1,676,000 shares of the company’s stock valued at $25,928,000 after acquiring an additional 1,634,000 shares in the last quarter. Bank of New York Mellon Corp grew its holdings in shares of Hims & Hers Health by 67.5% during the 2nd quarter. Bank of New York Mellon Corp now owns 678,602 shares of the company’s stock worth $13,701,000 after acquiring an additional 273,473 shares during the period. Finally, M&G Plc bought a new position in shares of Hims & Hers Health in the 1st quarter worth approximately $8,232,000. Institutional investors own 63.52% of the company’s stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.